Biological or pathological processes lead to changes in the composition of the proteome. The accurate analysis of such changes to individual proteins/biomarkers can be performed using antibody-based detection systems. The Multiplex Immunoassays Group at the NMI has over 20 years of experience in the development of multiplex immunoassays for this purpose. Multiplexing enables the analysis of multiple biomarkers simultaneously (e.g. all variants of SARS-CoV-2 or groups of proteins like Interferons). Based on their information density, multiplex assays are ideally suited to be applied in early/differentiation diagnosis, disease staging, or epidemiological studies, as well as in vaccine development.
In this presentation, Dr. Alex Dulovic will explain some of their current research activities, from assay development and utilization during the ongoing SARS-CoV-2 pandemic, to the ongoing work with other respiratory pathogens like RSV and Influenza, as well as future developments in the field of emerging infectious diseases such as Monkeypox.